A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer

Autor: Lattime E, Israeli R, Petrylak DP, Kaufman H, Plante M, DiPaola RS, Manson K, Schuetz T

Publikováno v: Journal of Translational Medicine, Vol 4, Iss 1, p 1 (2006)

Abstract Purpose Based on previous studies that demonstrated the safety profile and preliminary clinical activity of prostate specific antigen (PSA) targeted therapeutic vaccines, as well as recent laboratory data supporting the value of the addition

Externí odkaz: https://doaj.org/article/a916471698e74b47be6ee130e3f7e7af

Author Correction: Autophagy maintains tumour growth through circulating arginine.

Autor: Poillet-Perez L; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Xie X; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Zhan L; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Yang Y; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Sharp DW; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Hu ZS; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Su X; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA., Maganti A; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Jiang C; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Lu W; Department of Chemistry and Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA., Zheng H; Biological Mass Spectrometry Facility, Rutgers University, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ, USA., Bosenberg MW; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA., Mehnert JM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Medicine, Division of Medical Oncology, Developmental Therapeutics Unit, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA., Guo JY; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.; Department of Chemical Biology, Rutgers Ernest Mario School of Pharmacy, Piscataway, NJ, USA., Lattime E; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Surgery, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA., Rabinowitz JD; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Chemistry and Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA., White E; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. epwhite@cinj.rutgers.edu.; Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, NJ, USA. epwhite@cinj.rutgers.edu.

Publikováno v: Nature [Nature] 2019 Jan; Vol. 565 (7737), pp. E3.

Autophagy maintains tumour growth through circulating arginine.

Autor: Poillet-Perez L; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Xie X; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Zhan L; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Yang Y; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Sharp DW; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Hu ZS; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Su X; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA., Maganti A; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Jiang C; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Lu W; Department of Chemistry and Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA., Zheng H; Biological Mass Spectrometry Facility, Rutgers University, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ, USA., Bosenberg MW; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA., Mehnert JM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Medicine, Division of Medical Oncology, Developmental Therapeutics Unit, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA., Guo JY; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.; Department of Chemical Biology, Rutgers Ernest Mario School of Pharmacy, Piscataway, NJ, USA., Lattime E; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Surgery, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA., Rabinowitz JD; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Chemistry and Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA., White E; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. epwhite@cinj.rutgers.edu.; Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, NJ, USA. epwhite@cinj.rutgers.edu.

Publikováno v: Nature [Nature] 2018 Nov; Vol. 563 (7732), pp. 569-573. Date of Electronic Publication: 2018 Nov 14.

Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.

Autor: Panda A; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.; Department of Physics and Astronomy, Rutgers University, Piscataway, NJ., Betigeri A; Strand Life Sciences, Bangalore, India., Subramanian K; Strand Life Sciences, Bangalore, India., Ross JS; Foundation Medicine, Cambridge, MA., Pavlick DC; Foundation Medicine, Cambridge, MA., Ali S; Foundation Medicine, Cambridge, MA., Markowski P; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ., Silk A; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ., Kaufman HL; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ., Lattime E; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Mehnert JM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ., Sullivan R; Department of Medicine, Massachusetts General Hospital, Boston, MA., Lovly CM; Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN., Sosman J; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Johnson DB; Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN., Bhanot G; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.; Department of Physics and Astronomy, Rutgers University, Piscataway, NJ.; Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, NJ., Ganesan S; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2017; Vol. 2017. Date of Electronic Publication: 2017 Dec 07.

Shortwave‐Infrared‐Emitting Nanoprobes for CD8 Targeting and In Vivo Imaging of Cytotoxic T Cells in Breast Cancer.

Autor: Shah, Jay V.¹ (AUTHOR) jvshah93@gmail.com, Siebert, Jake N.¹ (AUTHOR), Zhao, Xinyu² (AUTHOR), He, Shuqing² (AUTHOR), Riman, Richard E.³ (AUTHOR), Tan, Mei Chee² (AUTHOR), Pierce, Mark C.¹ (AUTHOR), Lattime, Edmund C.⁴ (AUTHOR), Ganapathy, Vidya¹ (AUTHOR), Moghe, Prabhas V.^1,5 (AUTHOR) moghe@rutgers.edu

Publikováno v: Advanced Nanobiomed Research. Feb2024, Vol. 4 Issue 2, p1-12. 12p.